Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 3
2010 1
2011 1
2012 1
2014 2
2016 1
2017 3
2018 3
2019 7
2020 2
2021 3
2022 2
2023 8
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean mary newsline (2 results)?
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, Kurzrock R. Fujiwara Y, et al. Among authors: nesline mk. Cancer Treat Rev. 2022 Nov;110:102461. doi: 10.1016/j.ctrv.2022.102461. Epub 2022 Aug 30. Cancer Treat Rev. 2022. PMID: 36058143 Free article. Review.
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T. Brown LC, et al. Among authors: nesline mk. J Immunother Cancer. 2022 Oct;10(10):e005249. doi: 10.1136/jitc-2022-005249. J Immunother Cancer. 2022. PMID: 36252996 Free PMC article.
OX40/OX40 ligand and its role in precision immune oncology.
Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Previs RA, Conroy JM, DePietro P, Pabla S, Kurzrock R. Thapa B, et al. Among authors: nesline mk. Cancer Metastasis Rev. 2024 Mar 25. doi: 10.1007/s10555-024-10184-9. Online ahead of print. Cancer Metastasis Rev. 2024. PMID: 38526805 Review.
RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.
Severson E, Achyut BR, Nesline M, Pabla S, Previs RA, Kannan G, Chenn A, Zhang S, Klein R, Conroy J, Sausen M, Sathyan P, Saini KS, Ghosh A, Jensen TJ, Reddy P, Ramkissoon SH. Severson E, et al. Among authors: nesline m. J Mol Diagn. 2023 Jul;25(7):454-466. doi: 10.1016/j.jmoldx.2023.03.011. Epub 2023 May 8. J Mol Diagn. 2023. PMID: 37164276 Free article.
Identification of targets for prostate cancer immunotherapy.
Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C. Papanicolau-Sengos A, et al. Among authors: nesline m. Prostate. 2019 Apr;79(5):498-505. doi: 10.1002/pros.23756. Epub 2019 Jan 6. Prostate. 2019. PMID: 30614027
Challenges and prospects of CSF1R targeting for advanced malignancies.
Moeller A, Kurzrock R, Botta GP, Adashek JJ, Patel H, Lee S, Pabla S, Nesline MK, Conroy J, Sicklick JK, Kato S. Moeller A, et al. Among authors: nesline mk. Am J Cancer Res. 2023 Jul 15;13(7):3257-3265. eCollection 2023. Am J Cancer Res. 2023. PMID: 37560003 Free PMC article.
Immune profiling and immunotherapeutic targets in pancreatic cancer.
Lenzo FL, Kato S, Pabla S, DePietro P, Nesline MK, Conroy JM, Burgher B, Glenn ST, Kuvshinoff B, Kurzrock R, Morrison C. Lenzo FL, et al. Among authors: nesline mk. Ann Transl Med. 2021 Jan;9(2):119. doi: 10.21037/atm-20-1076. Ann Transl Med. 2021. PMID: 33569421 Free PMC article.
44 results